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1. Introduction
Adult hematopoietic stem cells (HSCs) ensure the maintenance of the HSC pool via their self-
renewal capacity, and replenish mature cells throughout life via their proliferation and
differentiation into lineage-restricted cells [1, 2]. HSCs are the only stem cells that have been
used in the clinic to treat diseases, such as leukemia, germ cell tumors, and congenital
immunodeficiencies. Since HSCs were first proposed [3], advances in multicolor flow cytom‐
etry have allowed the purification of mouse HSCs close to homogeneity. Several groups have
succeeded in long-term hematopoietic reconstitution by transplanting a single lineage of HSCs
(e.g., CD34low/- Kit+ Sca-1+ lineage marker-negative cells and CD150+ CD48- Kit+ Sca-1+ lineage
marker-negative cells), providing direct proof of the existence of HSCs [4-7]. More recently,
two groups analyzed the cycling status of HSCs by monitoring their proliferation rate over
several months in vivo. The results of these studies suggested the presence of dormant HSCs
that divide only about five times throughout the mouse life span [8, 9].
In the bone marrow (BM), HSCs are located in a specialized microenvironment, called the
niche. Under steady-state conditions, signals from niches maintain some HSCs in a dormant
state. Acquisition of dormancy is critical for the preservation of the self-renewal ability of HSCs
and for the prevention of premature stem cell exhaustion [10-12]. However, in response to
external stresses, such as bleeding, myeloablative chemotherapy and total body irradiation,
HSCs proliferate extensively to produce very large numbers of primitive progenitor cells,
thereby enabling rapid hematological regeneration [13]. Once recovery from myelosuppres‐
sion or other stresses has been achieved, the activated HSCs return to a quiescent state via a
number of negative feedback mechanisms [14]. This ability is a hallmark of HSCs and is
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fundamental for the maintenance of hematopoietic function throughout the life of the organ‐
ism. Although this property has long been recognized and is very important for organism
survival, the molecular basis underlying how HSCs react to a hematologic emergency remains
enigmatic. However, some key players have been identified. In this chapter, we briefly review
the recent advances in our knowledge of HSC cell-intrinsic and cell-extrinsic regulators that
are critical for hematopoietic regeneration under stress hematopoiesis.
2. Cell-intrinsic factors
2.1. Hemeoxygenase-1
Heme plays many important roles, such as in the promotion of proliferation and differentiation
of hematopoietic progenitor cells (HPCs) [15], and in the stimulation of hematopoiesis [16,
17]. Heme oxygenase (HO) catalyzes the degradation of heme. HO-1, encoded by the Hmox1
gene, is a stress-inducible isozyme of HO and is highly expressed in the BM and spleen [17].
Cao et al reported that the hematopoietic lineages of heterozygous HO-1-deficient mice
(HO-1+/-) display accelerated recovery from myelotoxic injury induced by 5-FU treatment. BM
transplantation experiments also revealed that mice transplanted with HO-1+/- BM cells
reconstituted hematopoietic lineages more rapidly than those transplanted with HO-1+/+ BM
cells. However, HO-1+/- HSCs could not rescue lethally irradiated recipient mice or serially
reconstitute irradiated mice [18]. These results suggest that HO-1 restricts the proliferation and
differentiation of HSCs/HPCs under stress conditions, and that the dysregulation of HO-1 can
lead to precocious HSC exhaustion.
2.2. PSF-1
PSF-1, a partner of sld five-1, forms a multiprotein complex, termed GINS. The GINS complex
contains Psf2, Psf3, and Sld5 in addition to Psf-1 [19-21]. All genes encoding this complex are
evolutionally conserved and are essential for cell growth [22]. Ueno et al isolated the mouse
orthlog of PSF1 from a BM Lin-c-Kit+Sca-1+ hematopoietic stem cell cDNA library and found
that PSF1 was specifically expressed in immature cells including blastocysts and spermato‐
gonia. They also generated PSF1-/- mice lacking functional PSF1, which died in utero around
the implantation stage [23]. In hematopoietic cells, PSF1 was highly expressed in CD34+ KSL
progenitor cells but not in CD34- KSL cells. In addition, proliferating CD34+ KSL cells sorted
from BM 4 days after 5-FU exposure were PSF1 positive. Next, Ueno et al investigated the
function of PSF1 in hematopoiesis using PSF1+/- mice. The pool size of HSCs and progenitor
cells was decreased in aged PSF1+/- mice compared to wild-type mice. Whereas young PSF1+/-
mice showed normal hematopoiesis under steady-state conditions, 5-FU treatment was lethal
in PSF1+/- mice as a result of a delay in the induction of HSC proliferation after BM ablation [24].
These results suggest that PSF1 is essential for the acute proliferation of HSCs during the
regeneration phase after BM suppression.
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2.3. Necdin
Necdin belongs to the melanoma antigen family of molecules, whose physiological roles have
not been well characterized [25]. Necdin was originally identified as a gene product induced
in neurally differentiated embryonal carcinoma cells [26]. Interestingly, recent genetic analyses
demonstrate that aberrant genomic imprinting of NDN on the human 15q11-q13 chromosomal
region is, at least in part, responsible for the pathogenesis of Prader-Willi syndrome [27-29], a
disease associated with a mildly increased risk of myeloid leukemia [30]. Necdin interacts with
multiple cell cycle-related proteins, such as SV-40 large T antigen, adenovirus E1A, E2F1, and
p53 [31-34]. We reported that necdin is one of 32 genes that show higher expression in HSCs
than in differentiated hematopoietic cells [35]. Other groups also found that necdin is highly
expressed in HSCs [36, 37]. Necdin-deficient mice show accelerated recovery of hematopoietic
systems after myelosuppressive stress, such as after 5-FU treatment and BM transplantation,
whereas no overt abnormality is seen under conditions of steady-state hematopoiesis. As
necdin is a potential negative cell cycle regulator, the enhanced hematologic recovery in
necdin-null mice was suggested to result from an increase in the number of proliferating HSCs
and progenitor cells. As expected, after 5-FU treatment, necdin-deficient mice had an increased
number of HSCs, but this increase was transient and was observed only during the recovery
phase [35]. These data suggest that the repression of necdin function in HSCs could form the
basis of a novel strategy for the acceleration of hematopoietic recovery, thereby providing
therapeutic benefits after clinical myelosuppressive treatments (e.g., cytoablative chemother‐
apy or HSC transplantation). Necdin is a p53 target gene, and in vitro overexpression and
knockdown experiments demonstrated that necdin plays a role in the maintenance of HSC
quiescence and self-renewal [37]. However, another group reported that necdin overexpres‐
sion does not result in enhanced HSC quiescence [38].
2.4. Slug
Slug is a member of the highly conserved Slug/Snail family of zinc-finger transcriptional
repressors found in diverse species ranging from C. elegans to humans. SLUG is a target gene
for the E2A-HLF chimeric oncoprotein in pro-B cell acute leukemia [39]. Slug is highly
expressed in immature hematopoietic cells, and a study using Slug-/- mice revealed that slug
is essential for the radioprotection of HPCs [40]. Slug is induced by p53 and protects immature
hematopoietic cells from apoptosis triggered by DNA damage. Slug exerts this function by
repressing Puma, a proapoptotic target of p53 [41]. Sun et al. investigated the effects of Slug
under steady-state and stress hematopoiesis [42]. The numbers of HSCs (LSK, Flk2—LSK,
SLAM, and EPCR+) and progenitor cells (multipotent progenitors: CD150—CD48—CD244+;
lineage-restricted progenitors: CD150—CD48+CD244+) were comparable regardless of the Slug
genotype under steady-state conditions. Consistent with previous reports [40, 43], they found
that hematopoiesis in the BM was normal in Slug-/- mice, suggesting that Slug is not required
for steady-state hematopoiesis. On the other hand, an in vivo competitive repopulation assay
revealed that Slug-deficient BM cells had a higher long-term reconstitution capacity. However,
HSC homing and differentiation were not affected by the deficiency of Slug. These results
suggest that Slug deficiency increases HSC self-renewal. Next, to assess whether Slug dosage
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affects HSC self-renewal capability, they performed a serial transplantation assay. Slug-/- BM
cells showed an enhanced repopulation capacity during serial transplantation. Furthermore,
the repopulating and proliferation potential of Slug-/- HSCs treated with 5-FU were also
examined in vivo and in vitro. Slug deficiency increased the reconstituting potential of 5-FU-
activated HSCs in vivo and accelerated HSC expansion in vitro. Taken together, these results
suggest that Slug negatively regulates HSC self-renewal under stress hematopoiesis.
2.5. Erg
The E-twenty-six (ETS)-related gene (ERG) belongs to the ETS family of transcription factors
[44]. ERG rearrangement has been reported in acute myeloid leukemia (AML) [45] and Ewing
sarcoma [46]. ERG overexpression has also been observed in prostate cancer [47]. A recent
study revealed that overexpression of ERG is an adverse prognostic factor in AML with a
normal karyotype [48]. More recently, the role of Erg in hematopoietic development and
normal hematopoiesis was investigated. Mld2, an allele of the murine Erg gene with a missense
mutation in the ETS domain-encoding region, disrupts Erg transactivation of gene expression.
Mice homozygous for the ErgMld2 allele die at midgestation because of a failure in definitive
hematopoiesis [49, 50]. Ng et al studied hematopoiesis in mice heterozygous for the ErgMld2
mutation [51]. While Erg+/Mld2 mice showed normal steady-state hematopoiesis, Erg+/Mld2 BM
cells exhibited defective HSC self-renewal in BM transplantation or during recovery from
exposure to sublethal γ-irradiation. The TPO/c-Mpl pathway is critical for the self-renewal and
proliferation of HSCs [52-54]. Next, the phenotype of Erg+/Mld2Mpl-/- mice was examined because
the Mld2 mutation was originally uncovered during a sensitized ENU mutagenesis screen of
Mpl-deficient mice [49]. The double mutant mice died of BM failure following an exacerbation
of a defect in HSC proliferation. Thus, Erg is required for HSC self-renewal during stress
hematopoiesis. ERG is also expressed in endothelial cells [55, 56]. A recent study showed that
ERG plays a role in endothelial tube formation and angiogenesis [57]. More recently, Yuan et
al identified Rhoj, a Rho GTPase family member, as a novel downstream target of ERG [58].
Interestingly, Rhoj is also highly expressed in HSCs [35].
3. Cell-extrinsic factors
The interaction between HSCs and their microenvironment (niche) is essential for HSC
maintenance, self-renewal, and survival. However, recent studies have revealed that the cell-
extrinsic factors provided by the BM niche are also important for HSC responses during
hematopoietic regeneration. Some key players have been identified.
3.1. Connexin-43
The exchange of ions, metabolites, and other small molecules (up to ~1,200 Da) occurs via gap
junctions. Gap junctions are configured by a large family of proteins known as connexins (Cxs).
In the connexin family, connexin-43 (Cx43) is highly expressed in BM stromal cells [59],
endothelial cells [7], osteoblasts [60], and mesenchymal stem cells [61]. HSCs also express Cx43
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[36]. Cx43-deficiency in the BM (Mx1-Cre/Cx43flox/flox) led to impaired hematopoietic recovery
after 5-FU treatment [62]. To clarify the mechanism of impaired hematopoietic regeneration
after myeloablation by 5-FU, Taniguchi-Ishikawa et al generated hematopoietic-specific Cx43
(H-Cx43)-deficient mice (Vav1-Cre/Cx43flox/flox) and analyzed their hematopoietic phenotype
[63]. The lack of Cx43 in hematopoiesis did not impair long-term competitive repopulation
capacity but impaired hematopoietic recovery after 5-FU administration. 5-FU-treated H-
Cx43-deficient HSCs failed to enter the cell cycle and showed decreased cell survival. More
detailed analyses revealed that enhanced quiescence in H-Cx43-deficient HSCs treated with
5-FU is associated with up-regulation of the expression of quiescence markers, p16INK4a [64]
and p38 [65], and with an increased level of intracellular reactive oxygen species (ROS).
The same group also investigated the role of Cx43 in the BM osteoblastic niche. For this,
Gonzalez-Nieto et al used conditionally osteoblast lineage-specific Cx43-deficient mice: Col1-
α1-Cre; Cx43flox/flox mice (OB/P Cx43-deficient mice) [66]. The OB/P Cx43-deficient mice showed
normal hematopoiesis under steady-state conditions. However, engraftment and migration of
normal HSCs was impaired by the loss of Cx43 in the osteoblast lineage. Interestingly, in
nonmyeloablated mice, OB/P Cx43 deficiency did not cause a homing defect but increased the
endosteal lodgment of HSCs, which was associated with the expansion of Cxcl-12-expressing
mesenchymal/osteolineage cells in the BM niche [67]. Another group reported that Cx43 and
Cx45 gap junctions mediate the secretion of CXCL12 from BM cells, resulting in HSCs adhesion
to stromal cells [68].
3.2. TIMP-3
Metalloproteinases (MMPs) modulate the extracellular matrix (ECM) environment [69-71].
Several studies have indicated that MMP-9 and MT1-MMP are important for the cleavage and
inactivation of the KIT ligand (Stem cell factor: SCF) and CXCL12 during G-CSF-induced
mobilization and hematopoietic recovery after cytotoxic stress in the BM [72-75]. Tissue
inhibitors of the metalloproteinase (TIMP) family consist of four members (TIMP-1 to -4), all
of which are endogenous regulators of metalloproteinases (MMPs) [76, 77]. Although TIMPs
were initially identified as inhibitors of MMPs, recent findings suggest that they might have
more diverse functions [78, 79]. Previous work suggested that TIMP-1 deficiency or enforced
expression of TIMP-1 or TIMP-2 does not alter steady-state hematopoiesis and stress hemato‐
poiesis, such as those induced by G-CSF stimulation and myelotoxic insult, respectively [80].
However, Rossi et al recently found that increased expression of p53 in TIMP-1-/- HSCs resulted
in dysregulation of the transition from G1 to S phase of the cell cycle, indicating that TIMP-1
has a role in controlling the cell cycle dynamics of LT-HSCs [81].
Among TIMP family members, TIMP-3 has unique properties. TIMP-3 binds firmly to ECM,
a disintegrin [82-84], and inhibits metalloproteinase domain-containing proteins, such as
ADAMs and ADAMTSs (ADAM proteins with Thrombospondin Motifs) [85]. Nakajima et al
found decreased expression of TIMP-3 in immune suppressor factor (ISF)/short form of ISF
(ShIF)-transfected cell lines, and partial reduction of HSC-supporting activity following the
restoration of TIMP-3 expression in stromal cells expressing ISF [86]. These authors also
investigated the role of TIMP-3 in HSC regulation. TIMP-3 expression in BM was increased
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after 5-FU injection, and addition or overexpression of TIMP-3 resulted in enhanced prolifer‐
ation of HSCs in vitro. BM regeneration after myelotoxic stress was impaired in TIMP-3-
deficient mice, but was accelerated by enforced expression of TIMP-3 in vivo [87]. Another
group also studied the role of TIMP-3 in hematopoiesis. They found that TIMP-3 was highly
expressed in the endosteal region of the BM, the HSC niche, whereas its expression was low
in HSCs and progenitor cells. They also examined the effect of human TIMP-3 (huTIMP-3)
overexpression in HSCs in vivo. TIMP-3 overexpression resulted in increased myelopoiesis
and decreased lymphopoiesis. Consistent with the study of Nakajima et al [87], HSC prolifer‐
ation was increased by huTIMP-3 overexpression in vitro and in vivo [88]. These results
suggest that TIMP-3 is important for the cellular response to myelosuppression.
3.3. Tenascin-C
Tenascin-C (TN-C) is a large extracellular matrix (ECM) glycoprotein that is expressed mainly
in the developing embryo [89]. In the adult BM, expression of TN-C is restricted to the endosteal
region [90, 91]. Although TN-C-deficient mice exhibit grossly normal development, the colony-
forming capacity of TN-C-/- BM cells is lower than that of wild-type BM cells [92]. This suggests
that TN-C makes a significant contribution under stress hematopoiesis because the mononu‐
clear cell count and BM architecture of TN-C-deficient mice are essentially normal. Nakamura-
Ishizu et al studied the function of TN-C during hematopoiesis in vivo using TN-C knockout
mice. First, they examined the expression pattern of various ECM proteins in the BM under
different conditions (steady-state, immediately after myeloablation, and during the hemato‐
poietic recovery phase). TN-C was predominantly expressed in stromal cells and endothelial
cells, which are components of the BM niche, and was markedly up-regulated in the BM during
hematopoietic regeneration. TN-C-/- mice showed defects in hematopoietic recovery after BM
ablation caused by 5-FU treatment and sublethal irradiation. The transplantation of wild-type
BM cells into TN-C-/- recipient mice demonstrated that a supporting ability of hematopoiesis
in BM microenvironment lacking TN-C is inadequate for the proliferation of transplanted wild-
type BM cells for the regeneration of hematopoiesis [93]. These findings suggest that TN-C is
a critical component of the BM microenvironment during hematopoietic regeneration.
4. Conclusions
In this chapter, we have briefly summarized regulators that have recently been shown to be
involved in the control of HSCs and progenitors during the hematopoietic regeneration phase.
Recent studies have revealed that, when myelopoiesis is compromised following infection,
HSC proliferation involves not only the factors described in this review, but also inflammatory
signaling molecules such as interferons [94-96], tumor necrosis factor-α [97, 98], and Toll-like
receptors [99-101]. Because HSC proliferation potential is critical for organism survival during
stress conditions, further understanding of the mechanism of stem cell activation will be
needed before stem cells can be used in regenerative medicine.
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